All-oral combination indicated for patients ineligible for intensive chemotherapy
— All-oral combination indicated for patients ineligible for intensive chemotherapy
by Ian Ingram, Managing Editor, MedPage Today
May 14, 2026
• 2 min read
The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy.
Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
Advancing Frontline Care With a Quadruplet Regimen for Transplant-Ineligible Myeloma Patients
BeOne wins FDA approval in lymphoma race
Tumori, una nuova immunoterapia disponibile per tre neoplasie
FDA blocked melanoma drug as confusion reigned under Makary
NHS drugs go-ahead offers lifeline to children with rare muscle-wasting disease
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
AstraZeneca follows Merck with Phase 3 win in bladder cancer
Astellas treatment offers new hope to a devastated rare disease community
FDA floats possible approach to repurpose approved drugs under new uses
Uno studio ha testato la combinazione di decitabina-cedazuridina e venetoclax nei pazienti over 75 e in cui la chemioterapia non…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer,…
Sonrotoclax (Beqalzi) indicated for relapsed or refractory mantle cell lymphoma
This article is sponsored by Johnson & Johnson. | Explore a quadruplet treatment regimen now approved for newly diagnosed…
Pioneering drug can halt advance of multiple myeloma for three times as long as standard treatments
